CNTX
NASDAQ · Pharmaceuticals
Context Therapeutics Inc
$2.79
-0.39 (-12.26%)
Financial Highlights (FY 2025)
Revenue
27.12M
Net Income
5.84M
Gross Margin
62.5%
Profit Margin
21.6%
Rev Growth
-4.2%
D/E Ratio
1.37
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 62.5% | 62.5% | 62.5% |
| Operating Margin | 24.1% | 23.8% | 19.5% |
| Profit Margin | 21.6% | 22.0% | 19.7% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 27.12M | 24.12M | 28.34M |
| Gross Profit | 16.96M | 15.08M | 17.72M |
| Operating Income | 6.54M | 5.74M | 5.51M |
| Net Income | 5.84M | 5.30M | 5.57M |
| Gross Margin | 62.5% | 62.5% | 62.5% |
| Operating Margin | 24.1% | 23.8% | 19.5% |
| Profit Margin | 21.6% | 22.0% | 19.7% |
| Rev Growth | -4.2% | +22.6% | +13.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 115.33M | 93.38M | 118.18M |
| Total Equity | 83.91M | 94.52M | 81.63M |
| D/E Ratio | 1.37 | 0.99 | 1.45 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 7.13M | 6.78M | 8.30M |
| Free Cash Flow | 3.88M | 4.04M | 6.28M |